Search
Recombinant stabilized RSV A prefusion F antigen
go.drugbank.com/drugs/DB18713ApprovedInvestigational[L48066] In contrast to another RSV vaccine, [respiratory syncytial virus vaccine, adjuvanted] (Arexvy), Abrysvo is reconstituted with sterile water prior to injection and does not require the co-administration … [L48066] Abrysvo was first approved by the FDA in May 2023 for use in patients ≥60 years of age, and received subsequent approval in August 2023 for use in pregnant individuals for the protection of
Ancestim
go.drugbank.com/drugs/DB09103ApprovedWithdrawnAncestim was developed by Amgen and sold to Biovitrium in December 2008. It was submitted to the FDA under the status of recommendation for approval with a 10 to 1 votes. … [T68] It was also approved by Health Canada in 1999 but it is currently under the status of canceled post-market.[L1087]
Albutrepenonacog alfa
go.drugbank.com/drugs/DB13884Approved[A32547] It was developed by CSL Behring Canada, Inc and approved by Health Canada on April 26, 2017. It was also approved by FDA and EMA in 2016.
Paroxetine
go.drugbank.com/drugs/DB00715ApprovedInvestigational[T653] It was approved by the FDA in the early 1990s and marketed by SmithKline Beecham. … Paroxetine is well tolerated in most patients with a similar adverse effect profile to other members of its drug class.
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeForeskin keratinocyte (neonatal)
go.drugbank.com/drugs/DB10772ApprovedOrcel, another skin substitute, is similar to Apligraf since it contains both fibroblasts and keratinocytes derived from neonatal foreskin, but in addition, utilizes a type I collagen sponge as its matrix … The barrier function of the skin owed to its avascular epidermal layer, which is made mainly of keratinocytes.
Natalizumab
go.drugbank.com/drugs/DB00108ApprovedInvestigational[A261331] On August 24, 2023, the first biosimilar to natalizumab, natalizumab-sztn, was approved by the FDA.[L48041] Natalizumab was approved by the European Commission on September 22, 2023. … In 2006, the FDA reintroduced the drug to the market for multiple sclerosis.[A261326] Natalizumab was further approved by the FDA for the treatment of Crohn's Disease in January 2008.
Aluminum zirconium tetrachlorohydrex gly
go.drugbank.com/drugs/DB11149ApprovedWithdrawnAluminum zirconium tetrachlorohydrex gly is a common active ingredient in personal care products as an antiperspirant agent. Its main mechanism of action is through blocking the pores via formation of polymer complex and preventing sweat...
Products: Mate Antiperspirant - Stk Top 20%, Arrid Xx Glide-ON Citrus Splash-gel Top 22%Iodide I-123
go.drugbank.com/drugs/DB09420ApprovedInvestigationalAfter incorporation, a gamma camera is used to detect the decay by electron capture to tellurium-123. … Following oral administration, I-123 is absorbed through the gastrointestinal tract and is taken up by the thyroid gland.
Durvalumab
go.drugbank.com/drugs/DB11714ApprovedInvestigational[A192789] Produced by recombinant DNA technology in Chinese Hamster Ovary (CHO) cell suspension culture,[L12621] durvalumab is a programmed death-ligand 1 (PD-L1) blocking antibody that works to promote … It was granted accelerated approval by the FDA in May 2017 [A192807] for the treatment of selected patients with locally advanced or metastatic urothelial carcinoma.
Foreskin fibroblast (neonatal)
go.drugbank.com/drugs/DB10770ApprovedDermagraft has been combined with [DB10772] to create a drug beneficial to patients with open burn wounds [L2427]. … work, in addition to decreased mortality [L2438].